This week, the secondary copper market showed a divergent pattern under the dual influence of improving macro expectations ...

A 12-week web-based, guided self-help program offers similar benefits as 20 weeks of standard treatment in reducing binge ...

Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients un ...

Retinal inner layer thinning detected by OCT offers a promising biomarker for monitoring multiple sclerosis progression.

At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...

Narcolepsy is not associated with increased risk for mortality of any type, even among patients with a higher prevalence of ...

Background The minimally important difference (MID) for frailty variation associated with adverse outcomes remains unknown in ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Suspension rates at some of the state’s largest public schools have nosedived – but at many campuses teachers are still ...

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.